Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT06794554

Status	RECRUITING
Phase	Phase 2
Sponsor	Mundipharma Research Limited
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (14)

- Willing and able to provide written informed consent
- Males or females e18 years of age
- Established diagnosis of CPA according to ESCMID/ERS criteria (2016) which includes all the following, which should be present for e3 months:
- one or more clinical symptoms (persistent cough, recurrent haemoptysis, weight loss, malaise, night sweats, fever and dyspnoea)
- slowly progressive or persistent radiological findings (one or more cavities and surrounding fibrosis, infiltrates, consolidation, with or without fungal ball or progressive pleural thickening) on computed tomography (CT) of the thorax

... and 9 more (see full listing online)

Exclusion (14)

- Subjects with invasive aspergillosis, aspergillus nodules, or simple aspergilloma
- Known or suspected hypersensitivity to rezafungin for Injection or any of its excipients
- Current participation in another interventional treatment trial with an investigational agent. Participation in another interventional treatment trial is permitted during the follow-up period of the study
- Recent use of an investigational medicinal product within 28 days or 5 half-lives of the investigational medicinal product, whichever is greater, to prevent overlapping toxicities when this study's investigational product is dosed, or presence of an investigational device at the time of screening. In some cases, use of investigational products may be acceptable in consultation with the Sponsor's Medical Monitor
- Administration of any other echinocandin or intravenous antifungal treatment within 3 months of screening

... and 9 more (see full listing online)

Locations (37 total)

Kepler University Hospital, Linz, Austria
Brussels University Hospital, Brussels, Belgium
UZ Gent, Ghent, Belgium
... and 34 more locations